Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-04-25

FDA Approved: TIROSINT — Supplemental Application (IBSA Pharma Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TIROSINT (levothyroxine sodium) submitted by IBSA Pharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TIROSINT (Levothyroxine Sodium)

Snippet

SUPPL AP for TIROSINT (LEVOTHYROXINE SODIUM)